This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Policy

LUX-Lung 2, 3 & 6 clinical data
GIOTRIF® was shown to be active in certain types of uncommon EGFR mutations known to be less responsive to reversible EGFR TKIs1

  • Activity was in the range of efficacy observed with GIOTRIF® in common EGFR mutations (del19 and L858R)1

EGFR =epidermal growth factor receptor; TKI=tyrosine kinase inhibitor; ORR= objective response rate

EGFR =epidermal growth factor receptor; TKI=tyrosine kinase inhibitor; CR= complete response; PR=partial response; DCR= disease control rate; ORR= objective response rate; NSCLC=non-small cell lung cancer

You may be interested in:

Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6

Yang et al., The Lancet Oncology, Volume 16, No. 7, p830–838, July 2015

Download the publication!

Learning about EGFR mutation testing in NSCLC

Clinical research studying the validity of different biomarkers has shifted the treatment paradigm in lung cancer with the discovery of the predictive and prognostic value of the EGFR and ALK biomarkers. Testing for biomarkers has become a crucial component when making treatment decisions in NSCLC, increasing the potential for personalised treatment in these typically hard-to-treat patients.2

NSCLC=non-small cell lung cancer; EGFR =epidermal growth factor receptor; ALK=anaplastic lymphoma kinase

Guidelines recommending routine testing for EGFR mutations and ALK rearrangements in all adenocarcinomas and other advanced nonsquamous NSCLC tumours

Major international societies including the NCCN, ESMO and CAP/IASLC/AMP guidelines recommend routine testing for EGFR mutations and ALK rearrangements in all adenocarcinomas and other advanced nonsquamous NSCLC tumours. Testing is recommended immediately after establishing histology or prior to initiating targeted therapy for a patient.3-5

Guidelines recommending routine testing for EGFR mutations and ALK rearrangements in all adenocarcinomas and other advanced nonsquamous NSCLC tumours

Clinical characteristics (e.g. age, gender, ethnicity, smoking history) do not provide the accuracy to be used to select patients for EGFR or ALK testing. Clinical characteristics alone should not be used to exclude or include patients from biomarker testing.5 Squamous cell never smokers, especially women, should also be tested for biomarkers.4

EGFR=epidermal growth factor receptor; ALK=anaplastic lymphoma kinase; NSCLC=non-small cell lung cancer; NCCN=national comprehensive cancer network; ESMO=european society for medical oncology; CAP= the college of American pathologists; IASLC= international association for the study of lung cancer; AMP= association for molecular pathology 

Is this information compelling to you?

Request contact
from Boehringer Ingelheim

References

  1. Yang JC et al. Lancet Oncol. 2015;16:830-838.
  2. Aisner DL and Marshall CB. Am J Clin Pathol. 2012;138(3):332–46.
  3. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology.V6; 2015.
  4. Kerr KM et al. Ann Oncol. 2014 Sep;25(9):1681–90.
  5. Lindeman NI et al. Arch Pathol Lab Med. 2013;137(6):828–60.
  6. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.
  7. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.
  8. Park K et al. Lancet Oncol. 2016;17(5):577-589.
  9. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.
  10. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.
  1. Sequist LV et al. J Clin Oncol. 2013;31(27):3327-3334.

  2. Wu YL et al. Lancet Oncol. 2014;15(2):213-222.

  3. Yang JC et al. Lancet Oncol. 2015;16(2):141-151.

  4. Park K et al. Lancet Oncol. 2016;17(5):577-589.

  5. Soria JC et al. Lancet Oncol. 2015;16(8):897-907.

  6. Solca F et al. J Pharmacol Exp Ther. 2012;343(2):342-350.

  7. Yang JC et al. J Clin Oncol. 2013;31(27):3342-3350.

  8. Hirsch V et al. Poster #369 presented at: American Society of Clinical Oncology (ASCO) Annual Meeting; Chicago, IL, USA; 3-7 June 2016.

  9. Yang JCH et al. Ann Oncol. 2016;27(11):2103-2110.

  10. Schuler M et al. J Thorac Oncol. 2016;11(3):380-390.

  11. Paz-Arez L et al. Ann Oncol. 2017; doi: 10.1093/annonc/mdw611.

  12. GIOTRIF® (afatinib) Summary of Product Characteristics, 2016.

Report an adverse event

If you wish to report an adverse event (AE) after treatment with one of our products, please select your site from the link below. This will allow reporting of AEs in line with the reporting procedure effective in your country for reporting.

Boehringer Ingelheim local websites
Back to top